RxDoctor Payments Data

Seth Meskin, MD

Ophthalmology · Milford, CTNPI 1346273273

Payments from drug & device makers

$648in general payments, 2019–2025

Across 32 payments — averaging $20.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$83
  • Sun Pharmaceutical Industries Inc.$82
  • Kala Pharmaceuticals, Inc.$68
  • Regeneron Healthcare Solutions, Inc.$67
  • Tarsus Pharmaceuticals, Inc.$66
  • Dompe US, Inc.$52
  • plus $229 from 9 others

What the payments were for

  • Food & beverage$648100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$648 in reported general payments places this provider in the 45th percentile of 279 ophthalmology providers in Connecticut.

See all ophthalmology providers in Connecticut

Medicare billing

Part B allowed, 2024
$179,760
Medicare patients
358
Services billed
1,392

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine111$162,784
MieboPerfluorohexyloctane/Pf72$52,941
Cyclosporine73$43,210
XiidraLifitegrast29$38,928
LotemaxLoteprednol Etabonate42$27,493
Loteprednol Etabonate119$27,468
Prednisolone Acetate262$11,308
Fluorometholone136$11,239
ValacyclovirValacyclovir Hcl113$10,293
ProlensaBromfenac Sodium24$8,278
Pred FortePrednisolone Acetate34$8,028
MoxifloxacinMoxifloxacin Hcl232$6,450
Bromfenac Sodium52$6,077
CombiganBrimonidine Tartrate/Timolol11$5,046
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol23$4,958

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Combigan$83$167,829122 claims
Bausch & Lomb Americas Inc.Miebo, Xiidra$35$91,870101 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax, Loteprednol Etabonate, Prolensa$20$63,239185 claims
AlconSimbrinza$40$3,20915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 279 ophthalmology providers in Connecticut.

Other ophthalmology in Milford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →